Plasmacure Secures €16M to Revolutionize Chronic Wound Healing with Cold Plasma Innovation

Plasmacure is thrilled to announce that it has successfully raised €16,000,000 in new funding, marking a significant milestone in its mission to transform chronic wound care. As a leader in transitioning from traditional treatments to technology-driven solutions, Plasmacure is at the forefront of addressing a €70B global industry challenged by aging populations and rising incidences of conditions like diabetes that exacerbate chronic wounds. This substantial investment will accelerate the deployment of Plasmacure’s patented PLASOMA cold plasma system—a CE-marked, medical device class IIb innovation that has been proven in randomized controlled trials to be 2.5 times more effective at closing complex wounds compared to existing protocols. With the funds secured, the company plans to expand its commercially available system that integrates a unique pulser unit and disposable cold plasma pads, engineered to safely deliver plasma directly to wound sites. This breakthrough technology not only offers improved healing outcomes but also has the potential to reduce healthcare costs by more than 40% and cut staff workload by over 50%, making it an attractive solution for both in-clinic and home use. Plasmacure’s vision has already begun to reshape wound care in the Netherlands and other key markets, and this round of funding will further bolster its research, production, and global distribution efforts. The company is excited to further collaborate with esteemed partners and investors such as NextGen Ventures, OostNL, and The European Economic Council as it continues its mission to ensure that patients suffering from diabetic foot ulcers, leg ulcers, pressure ulcers, burns, and other chronic wounds receive swift, effective, and convenient care.